Suzhou Qiaoji Biotechnology

Suzhou Qiaoji Biotechnology is a China-based biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for historically undruggable targets in oncology. Headquartered in the Suzhou Industrial Park, the company leverages its proprietary drug discovery platform to target high-value oncogenic drivers, with a primary focus on the RAS signaling pathway. Its lead program, QJ-001, is a potent and selective KRAS G12D inhibitor currently in the IND-enabling phase for the treatment of solid tumors such as pancreatic and colorectal cancers. Qiaoji Biotech aims to address significant unmet medical needs by developing next-generation precision medicines through advanced structural biology and medicinal chemistry.